688298 东方生物
2025/09 - 九个月
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额(154,633)(348,327)(1,645,591)2,995,9245,203,854
投资活动产生之现金流量净额(313,707)(670,150)(2,117,755)(2,375,700)(321,637)
筹资活动产生之现金流量净额(220,713)(451,737)49,536(698,248)(509,174)
汇率变动对现金及现金等价物的影响(2,910)51,88685,852536,645(75,440)
现金及现金等价物净增加/(减少)(691,963)(1,418,328)(3,627,957)458,6224,297,603
期初现金及现金等价物余额1,510,2752,928,6036,556,5606,097,9381,800,335
期末现金及现金等价物余额818,3121,510,2752,928,6036,556,5606,097,938